Browse the evidence

Obese individuals with hypertension, dyslipidemia, type 2 diabetes mellitus, and cardiovascular disease may have better outcomes than their lean counterparts.

Healthcare providers should consider the potential for better outcomes in obese patients with certain conditions compared to lean patients.

BMI does not differentiate between types of adiposity.

Practitioners should be cautious in using BMI as a sole indicator of health due to its limitations.

The term 'obesity paradox' may reflect a lack of understanding of the complex pathophysiology of obesity.

Understanding the complexities of obesity may help in better addressing its health implications.

Gut microbiota dysbiosis impairs GLP-1 secretion, contributing to the progression of degenerative musculoskeletal diseases (osteoarthritis, osteoporosis, sarcopenia, and intervertebral disc degeneration).

Degenerative joint and muscle issues in aging may be linked to gut health. Restoring a healthy gut microbiome through diet (fiber/prebiotics), probiotics, or fecal microbiota transplantation (FMT) may help restore natural GLP-1 levels, potentially slowing disease progression. This is a supportive strategy, not a standalone cure.

GLP-1 exerts protective effects on musculoskeletal tissues (bone, cartilage, muscle, disc) by reducing inflammation, oxidative stress, and apoptosis.

Maintaining healthy GLP-1 levels (via gut health) may help protect joints and muscles from age-related degeneration by reducing inflammation and cell death.

Elderly adults have reduced mitochondrial capacity and a trend for decreased coupling efficiency compared to young adults.

Practitioners should consider the impact of aging on mitochondrial function when addressing metabolic health in elderly populations.

Elderly adults exhibit greater whole-body oxidative stress and less skeletal muscle mass compared to young adults.

Understanding the relationship between oxidative stress and muscle mass can help in developing interventions for elderly health.

Elderly adults have lower glucose tolerance compared to young adults.

This finding highlights the importance of monitoring glucose levels in elderly populations for better health management.

Cross-sectional studies show significant correlations between the four metabolic parameters and body size.

Understanding these correlations can help in evaluating body composition.

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.

Exercise has not increased proportional to exercise advice given to patients.

There is a need for strategies to translate exercise advice into actual behavior change.

Diet quality among U.S. adults improved modestly between 1999 and 2020.

Practitioners should note a modest improvement in diet quality over the past two decades.

The proportion of U.S. adults with poor diet quality remains high.

Practitioners should be aware that many adults still have poor diet quality.

Dietary disparities persist or are worsening among U.S. adults.

Practitioners should focus on addressing dietary disparities in their communities.

GLP-1 receptor agonists delay gastric emptying via peripheral and central nervous system pathways, creating a significant risk of retained gastric contents and pulmonary aspiration during anesthesia even when standard preoperative fasting guidelines are followed.

If you take a GLP-1 medication (like Ozempic, Wegovy, or Mounjaro) and are scheduled for surgery, you must inform your anesthesiologist and endocrinologist. Do not assume standard fasting rules apply. Your stomach may still contain food, increasing the risk of serious lung complications during anesthesia. Your care team may need to adjust your fasting instructions, postpone elective surgery, or use special techniques to protect your airway.

Short-acting GLP-1 RAs cause more pronounced delays in gastric emptying than long-acting agents, although long-acting agents may still pose aspiration risks due to residual effects depending on dose and treatment duration.

Know which GLP-1 medication you take. Short-acting drugs (like Byetta or Trulicity's short-acting cousin) tend to slow your stomach more than long-acting ones (like Ozempic or Mounjaro). However, even long-acting drugs can keep food in your stomach if you took a dose recently. Always tell your surgical team exactly when you took your last dose.

9% of Colorado firefighters have metabolic syndrome (MetS), with 5% of females and 10% of males affected.

Firefighters should be screened for MetS to manage cardiovascular health risks.

In non-beta tissues (liver, kidney, skeletal muscle, adipose), the mitochondrial benefits of GLP-1RAs are likely a combination of direct receptor signaling and indirect systemic improvements such as weight loss and reduced inflammation.

While GLP-1 drugs improve mitochondrial health in organs like the liver and muscles, these benefits are partly due to the overall reduction in body weight and blood sugar. It is a combined effect of losing weight and the drug's direct action on cells.

The mean usual intake of energy among Iranian middle-aged and elderly people is 1749.2 kcal based on the NCI method.

Practitioners should consider the average energy intake when designing dietary interventions.

Carbohydrate constitutes 59.98% and protein 17.42% of total energy intake in this population.

Understanding macronutrient distribution can help tailor dietary recommendations.

Approximately 7% of studied females aged 51-70 years met the recommended or higher levels for fibre.

There is a need for increased focus on fibre intake among older females.

The proportion of new users of semaglutide (Ozempic ® ) with a record of type 2 diabetes (T2D) declined from 99% in 2018 to only 67% in 2022, before increasing again to 87% in 2023.

Practitioners should note the changing demographics of semaglutide users, indicating a shift towards off-label use.

Most initiators of semaglutide (Ozempic ® ) with T2D had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol.

Practitioners should be aware that many T2D patients starting semaglutide may not have optimal glucose control.

Most studies on lifestyle modifications in diabetes were of relatively short duration.

There is a need for more long-term studies on lifestyle modifications in diabetes.